Early de-risking and prediction of human safety in drug discovery
Date: July 4, 2024
Time: 12:00 - 13:00
Location: Room 5
Speaker: Paul Walker Ph.D. (VP Head of Toxicology and Innovation Efficiency)
We present in vitro approaches and associated safety cascades to de-risk small chemical entities (NCEs) in early drug discovery. Using in vitro models of human relevance such as human liver microtissues (hLiMTs) and cardiac tri-culture organoids. Human safety prediction is determined with combining these in vitro models with 3D high content imaging (HCI) and full genome transcriptomics (Tx). AI/ML models are utilised to determine a human safety risk profile.
High-throughput RNA sequencing combined with multiparametric in vitro assays for cardiotoxicity risk assessment and mechanistic determination
Date: July 5, 2024
Time: 11:00 - 11:12
Location: Room 5, Oral Session 7
Speaker: Paul Walker Ph.D. (VP Head of Toxicology and Innovation Efficiency)
Drug-induced cardiotoxicity can alter cardiac electrophysiology and structure, necessitating predictive models for improved cardiac safety. We assessed 163 reference compounds in hiPSC-derived cardiomyocytes using high-content imaging, calcium transient monitoring, and RNA sequencing in a combined approach that provided high prediction accuracy, enabling early detection and risk assessment of cardiotoxicity mechanisms in drug discovery.
